NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Epitome Therapeutics

Epitome Therapeutics

Private
ViennaHealthcare & Life Scienceshttps://epitome-tx.com/

Last Round

Grant

Jun 30, 2026

Total Funding Raised

$2.28M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Epitome Therapeutics is a biotechnology company developing CADENCE, a programmable platform for precise and durable activation of endogenous genes to treat severe liver and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

epigenome editinggene expression controlepigenetic therapydurable gene activationno-cut gene editingliver disease therapymetabolic disease therapyCRISPR-based epigenome editinglipid nanoparticlesLNP deliverygene therapytherapeutic platformplatform licensingprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epitome Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Epitome Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Epitome Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 30, 2026

Epitome Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 30, 2026

    $2.3M round led by Caesar Ventures and xista science ventures.

Epitome Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Epitome Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Epitome Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Year Founded2024
Last FundingJun 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.